172 related articles for article (PubMed ID: 38159438)
1. Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.
Ibrahim R; Assi T; Khoury R; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
Cancer Treat Rev; 2024 Feb; 123():102675. PubMed ID: 38159438
[TBL] [Abstract][Full Text] [Related]
2. The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects.
Zheng C; Huang J; Xu G; Li W; Weng X; Zhang S
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166907. PubMed ID: 37793461
[TBL] [Abstract][Full Text] [Related]
3. Current management and recent progress in desmoid tumors.
Zhou MY; Bui NQ; Charville GW; Ghanouni P; Ganjoo KN
Cancer Treat Res Commun; 2022; 31():100562. PubMed ID: 35460976
[TBL] [Abstract][Full Text] [Related]
4. Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.
Chan D; Kaplan J; Gordon G; Desai J
Curr Oncol; 2021 Sep; 28(5):3659-3667. PubMed ID: 34590610
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.
McLean TD; Duchi S; Di Bella C
Target Oncol; 2022 May; 17(3):223-252. PubMed ID: 35446005
[TBL] [Abstract][Full Text] [Related]
6. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Kummar S; O'Sullivan Coyne G; Do KT; Turkbey B; Meltzer PS; Polley E; Choyke PL; Meehan R; Vilimas R; Horneffer Y; Juwara L; Lih A; Choudhary A; Mitchell SA; Helman LJ; Doroshow JH; Chen AP
J Clin Oncol; 2017 May; 35(14):1561-1569. PubMed ID: 28350521
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects.
Wang Z; Wu J; Tian X; Hao C
Front Med; 2019 Aug; 13(4):427-437. PubMed ID: 30798508
[TBL] [Abstract][Full Text] [Related]
8. Desmoid-type fibromatosis: toward a holistic management.
Penel N; Kasper B; van Der Graaf WTA
Curr Opin Oncol; 2021 Jul; 33(4):309-314. PubMed ID: 33973549
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors.
Shang H; Braggio D; Lee YJ; Al Sannaa GA; Creighton CJ; Bolshakov S; Lazar AJ; Lev D; Pollock RE
Cancer; 2015 Nov; 121(22):4088-96. PubMed ID: 26349011
[TBL] [Abstract][Full Text] [Related]
10. The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors.
Douglass DP; Navid F; Weiss AR
Paediatr Drugs; 2022 Sep; 24(5):433-445. PubMed ID: 35902507
[TBL] [Abstract][Full Text] [Related]
11. Evolving strategies for management of desmoid tumor.
Riedel RF; Agulnik M
Cancer; 2022 Aug; 128(16):3027-3040. PubMed ID: 35670122
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Villalobos VM; Hall F; Jimeno A; Gore L; Kern K; Cesari R; Huang B; Schowinsky JT; Blatchford PJ; Hoffner B; Elias A; Messersmith W
Ann Surg Oncol; 2018 Mar; 25(3):768-775. PubMed ID: 28887726
[TBL] [Abstract][Full Text] [Related]
13. TGF-β and CTGF are Mitogenic Output Mediators of Wnt/β-Catenin Signaling in Desmoid Fibromatosis.
Varghese S; Braggio DA; Gillespie J; Toland AE; Pollock R; Mayerson J; Scharschmidt T; Iwenofu OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):559-565. PubMed ID: 26894649
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Takahashi T; Prensner JR; Robson CD; Janeway KA; Weigel BJ
Pediatr Blood Cancer; 2020 Oct; 67(10):e28636. PubMed ID: 32762028
[TBL] [Abstract][Full Text] [Related]
15. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Gounder M; Ratan R; Alcindor T; Schöffski P; van der Graaf WT; Wilky BA; Riedel RF; Lim A; Smith LM; Moody S; Attia S; Chawla S; D'Amato G; Federman N; Merriam P; Van Tine BA; Vincenzi B; Benson C; Bui NQ; Chugh R; Tinoco G; Charlson J; Dileo P; Hartner L; Lapeire L; Mazzeo F; Palmerini E; Reichardt P; Stacchiotti S; Bailey HH; Burgess MA; Cote GM; Davis LE; Deshpande H; Gelderblom H; Grignani G; Loggers E; Philip T; Pressey JG; Kummar S; Kasper B
N Engl J Med; 2023 Mar; 388(10):898-912. PubMed ID: 36884323
[TBL] [Abstract][Full Text] [Related]
16. [Desmoid-type fibromatosis (aggressive fibromatosis)].
Kuhnen C; Helwing M; Rabstein S; Homann HH; Müller KM
Pathologe; 2005 Mar; 26(2):117-26. PubMed ID: 15657684
[TBL] [Abstract][Full Text] [Related]
17. Optimal therapy for desmoid tumors: current options and challenges for the future.
Al-Jazrawe M; Au M; Alman B
Expert Rev Anticancer Ther; 2015; 15(12):1443-58. PubMed ID: 26472625
[TBL] [Abstract][Full Text] [Related]
18. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
[TBL] [Abstract][Full Text] [Related]
19. Management of Desmoid Tumors.
Spolverato G; Capelli G; Kasper B; Gounder M
Surg Oncol Clin N Am; 2022 Jul; 31(3):447-458. PubMed ID: 35715144
[TBL] [Abstract][Full Text] [Related]
20. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
